ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC (NCT05682443)

🧪 Interventions in This Study

• ONC-392 low (DRUG)
• ONC-392 high (DRUG)
• lutetium Lu 177 vipivotide tetraxetan (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (23 Sites)

• UC Davis Comprehensive Cancer Center — Sacramento, California
• Rocky Mountain Cancer Centers USOR — Aurora, Colorado
• Moffitt Cancer Cancer — Tampa, Florida
• Emory University Winship Cancer Institute — Atlanta, Georgia
• The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — Baltimore, Maryland
• Chesapeake Urology Research Associates — Towson, Maryland
• Lahey Hospital & Medical Center — Burlington, Massachusetts
• University of Mississippi Medical Center — Jackson, Mississippi
• XCancer/GU Research Network — Omaha, Nebraska
• Rutgers Cancer Institute — New Brunswick, New Jersey
• New Mexico Oncology Hematology Consultants — Albuquerque, New Mexico
• Roswell Park Comprehensive Cancer Center — Buffalo, New York
• NYU Langone Health, Laura & Isaac Perlmutter Cancer Center — New York, New York
• Columbia University Irving Cancer Center — New York, New York
• UNC North Carolina Comprehensive Cancer Care Center — Chapel Hill, North Carolina
• Duke Cancer Center — Durham, North Carolina
• The Ohio State University Comprehensive Cancer Center — Columbus, Ohio
• OHSU Knight Cancer Institute — Portland, Oregon
• UT Southwestern Medical Center — Dallas, Texas
• Virginia Cancer Specialists USOR — Fairfax, Virginia
• Virginia Oncology Associates USOR — Norfolk, Virginia
• Oncology and Hematology Associates Of Southwest Virginia USOR — Norton, Virginia
• UW Carbone Cancer Center — Madison, Wisconsin

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Metastatic Castration-resistant Prostate Cancer

• A Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer — San Francisco, California
• Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment — Tucson, Arizona
• FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) — Duarte, California
• A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer — Duarte, California
• FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer — San Francisco, California

Explore by condition: All Metastatic Castration-resistant Prostate Cancer clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Review the official NIH record below to find the coordinating site.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.